Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06131398 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 20
- Study locations
NCT06131398: Active Phase 1 study of Advanced Solid Tumors, sponsored by Amgen.
NCT06131398 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 77 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06131398, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG AMG 355
Study Locations (20)
Other
- Institut Bergonie - Bordeaux
- Gustave Roussy - Villejuif
- Radboud Universitair Medisch Centrum - Nijmegen
- Erasmus Medisch Centrum - Rotterdam
- Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy - Warsaw
- Seoul National University Hospital - Seoul
- Asan Medical Center - Seoul
Catalonia
- Hospital Universitari Vall d Hebron - Barcelona
- Hospital Clinic i Provincial de Barcelona - Barcelona
California
- City of Hope National Medical Center - Duarte
Kansas
- Alliance for Multispecialty Research - Kansas City - Merriam
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University - St Louis
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2026-08-03 |
| Phase | Phase 1 |
What the registry record for NCT06131398 still lists
NCT06131398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06131398 names 20 study sites across 13 states, led by Other, Catalonia, California.
Frequently Asked Questions
What is clinical trial NCT06131398 about?
NCT06131398 is a clinical study titled "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors". The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in co...
What is the current status of trial NCT06131398?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2024-03-07. Estimated completion is 2026-08-03.
What conditions does trial NCT06131398 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06131398?
The interventions under investigation include: Pembrolizumab (DRUG), AMG 355 (DRUG).
Who is sponsoring clinical trial NCT06131398?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06131398 being conducted?
This trial has 20 study locations across California, Kansas, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06131398's enrollment target sits among peer trials
77 91st of 144 higher than 54 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI